De-novo malignancies after kidney transplantation: A long-term observational study

PLoS One. 2020 Nov 30;15(11):e0242805. doi: 10.1371/journal.pone.0242805. eCollection 2020.

Abstract

Background: De-novo malignancies after kidney transplantation represent one major cause for mortality after transplantation. However, most of the studies are limited due to small sample size, short follow-up or lack of information about cancer specific mortality.

Methods: This long-term retrospective analysis included all adult patients with complete follow-up that underwent kidney transplantation between 1995 and 2016 at our centre. All patients with diagnosis of malignancy excluding non-melanoma skin cancer (NMSC) were identified and a matched control group was assigned to the kidney transplant recipients with post-transplant malignancies.

Results: 1417 patients matched the inclusion criteria. 179 malignancies posttransplant were diagnosed in 154 patients (n = 21 with two, n = 2 patients with three different malignancies). Mean age at cancer diagnosis was 60.3±13.3 years. Overall incidence of de-novo malignancies except NMSC was 1% per year posttransplant. Renal cell carcinoma was the most common entity (n = 49, incidence 4.20 per 1000 patient years; cancer specific mortality 12%), followed by cancer of the gastro-intestinal tract (n = 30, 2.57; 50%), urinary system (n = 24, 2.06; 13%), respiratory system (n = 18, 1.54; 89%), female reproductive system (n = 15, 1.29; 13%), posttransplant lymphoproliferative disorders and haematological tumours (n = 14, 1.20; 21%), cancers of unknown primary (n = 7, 0.60 100%) and others (n = 22, 1.89; 27%). Male sex, re-transplantation and time on dialysis were associated with de-novo malignancies after transplantation.

Conclusion: De-novo malignancies continue to be a serious problem after kidney transplantation. To improve long-term outcome after Kidney transplantation, prevention and cancer screening should be more tailored and intensified.

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Renal Cell / diagnosis*
  • Carcinoma, Renal Cell / epidemiology
  • Carcinoma, Renal Cell / etiology
  • Carcinoma, Renal Cell / pathology
  • Female
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation / adverse effects*
  • Liver Transplantation / adverse effects
  • Longitudinal Studies
  • Lymphoproliferative Disorders / diagnosis*
  • Lymphoproliferative Disorders / epidemiology
  • Lymphoproliferative Disorders / etiology
  • Lymphoproliferative Disorders / pathology
  • Male
  • Middle Aged
  • Neoplasms / diagnosis*
  • Neoplasms / epidemiology
  • Neoplasms / etiology
  • Neoplasms / pathology
  • Retrospective Studies

Substances

  • Immunosuppressive Agents

Grants and funding

The authors received no specific funding for this work.